Tiziana licenses anti-inflammatory foralumab from Novimmune

Oncology and immunology specialist Tiziana and antibody-based drug manufacturer Novimmune have entered into an agreement whereby Novimmune grants Tiziana an exclusive license for the clinical development and commercialization of foralumab.

Foralumab is a fully-human antihuman CD3 receptor monoclonal antibody. It is currently in Phase II development with potential application in several autoimmune and inflammatory diseases such as multiple sclerosis, psoriasis and rheumatoid arthritis where modulating a T-cell response to achieve immunosupppression is desirable.

Tiziana will pay an upfront fee of $1.25 million for the license to Novimmune within 60 days after signing the agreement and will make further payments to Novimmune to the total value of $750,000 by February 2018. Tiziana will also pay a royalty on sales or a share of sub-licence revenues to Novimmune, minus certain costs.